Selection and Review Committee (SRC) Announced
MedChem Australia is proud to introduce its Selection and Review Committee (SRC), a fantastic assembly of 13 independent experts from across Australia to steer the organisation’s project selection and review processes. Comprising leading figures from academia, industry, and the clinic, the SRC embodies a wealth of knowledge across drug discovery disciplines, with specialised expertise spanning various therapeutic areas.
Chair of the SRC is Dr. Susan Pond AM, FRSN FTSE FAHMS, a preeminent leader in the fields of medicine, science, and corporate governance. Dr. Pond brings an unparalleled depth of experience within the Australian biotechnology landscape, making her an ideal choice to lead the SRC’s activities.
MedChem Australia extends its gratitude to all SRC members. Their collective expertise and dedication will play a pivotal role in steering MedChem Australia toward innovative and impactful projects in the upcoming years.
“We are privileged to have such a distinguished group of experts on our Selection and Review Committee,” said Prof. Brendon Monahan, Director of MedChem Australia. “Their diverse backgrounds and collective wisdom will undoubtedly contribute to the success of MedChem Australia as we embark on a new chapter of collaborative drug discovery.”
With the SRC now in place, MedChem Australia continues to advance through its establishment phase and, along with its first call for projects, the Initiative is poised to select, and subsequently begin, innovative drug discovery projects in the first half of 2024.